Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1995-06-07
2000-11-28
Wortman, Donna C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
4241781, 5147721, A61K 3817
Patent
active
061531936
ABSTRACT:
Improved pharmaceutical compositions useful in targeting biological agents to particular tissue and compositions useful for administering biological agents to the brain.
REFERENCES:
patent: 4027013 (1977-05-01), Bick et al.
patent: 4188373 (1980-02-01), Krezanoski
patent: 4474752 (1984-10-01), Haslam et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4740498 (1988-04-01), Hirao et al.
patent: 4772466 (1988-09-01), Alison et al.
patent: 4801452 (1989-01-01), Hunter et al.
patent: 4837014 (1989-06-01), Hunter et al.
patent: 4865835 (1989-09-01), Begent
patent: 4873083 (1989-10-01), Hunter et al.
patent: 4879109 (1989-11-01), Hunter
patent: 4882168 (1989-11-01), Casey et al.
patent: 4897263 (1990-01-01), Hunter
patent: 4937070 (1990-06-01), Hunter
patent: 4957735 (1990-09-01), Huang
patent: 4997644 (1991-03-01), Hunter
patent: 5017370 (1991-05-01), Hunter et al.
patent: 5028599 (1991-07-01), Hunter
patent: 5030448 (1991-07-01), Hunter
patent: 5032394 (1991-07-01), Hunter
patent: 5039520 (1991-08-01), Hunter
patent: 5041288 (1991-08-01), Hunter
patent: 5047236 (1991-09-01), Hunter et al.
patent: 5064643 (1991-11-01), Hunter et al.
patent: 5071649 (1991-12-01), Hunter
patent: 5078995 (1992-01-01), Hunter et al.
patent: 5080894 (1992-01-01), Hunter et al.
patent: 5089260 (1992-02-01), Hunter et al.
patent: 5114708 (1992-05-01), Hunter et al.
patent: 5152979 (1992-10-01), Hunter
patent: 5182106 (1993-01-01), Mezrow et al.
patent: 5183687 (1993-02-01), Hunter et al.
patent: 5198211 (1993-03-01), Hunter et al.
patent: 5234683 (1993-08-01), Hunter et al.
patent: 5240701 (1993-08-01), Hunter et al.
patent: 5240702 (1993-08-01), Hunter et al.
patent: 5250294 (1993-10-01), Hunter et al.
patent: 5412072 (1995-05-01), Sakurai et al.
patent: 5417982 (1995-05-01), Modi
patent: 5436170 (1995-07-01), Cornell et al.
patent: 5449513 (1995-09-01), Yokoyama et al.
patent: 5466445 (1995-11-01), Hunter
patent: 5470568 (1995-11-01), Lee
patent: 5488034 (1996-01-01), McGregor et al.
patent: 5494660 (1996-02-01), Hunter et al.
patent: 5523492 (1996-06-01), Emanuele et al.
patent: 5531925 (1996-07-01), Landh et al.
patent: 5554372 (1996-09-01), Hunter
patent: 5567859 (1996-10-01), Emanuele et al.
patent: 5573934 (1996-11-01), Hubbel et al.
patent: 5591715 (1997-01-01), Coon et al.
patent: 5622649 (1997-04-01), Hunter et al.
patent: 5648071 (1997-07-01), Hunter et al.
patent: 5656611 (1997-08-01), Kabanov et al.
patent: 5674911 (1997-10-01), Emanuele et al.
patent: 5691387 (1997-11-01), Emanuele et al.
patent: 5696090 (1997-12-01), McGregor et al.
patent: 5696298 (1997-12-01), Emanuele et al.
patent: 5698529 (1997-12-01), Alakhov et al.
patent: 5776891 (1998-07-01), Coon et al.
patent: 5840319 (1998-11-01), Alakhov et al.
patent: 5885590 (1999-03-01), Hunter et al.
patent: 6040295 (2000-02-01), Rolland et al.
Kabanov et al., The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. FEBS Letters 258(2):343-345, 1989.
Chekhonin et al., Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain. FEBS Letters 287(1,2);149-152, 1991.
Kabanov et al., A new class of drug carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain. Journal of Controlled Release 22:141-157, 1992.
Budavari et al., Eds., The Merck Index, Eleventh Edition, Merck & Co., Rahway, NJ, 1989, p. 712.
Chekhonin et al., "Fatty Acid Acylated Fab-Fragments Of Antibodies To Neurospecific Proteins As Carriers For Neuroleptic Targeted Delivery In Brain", FEBS Lett., 287, N 1,2, 149-152 (1991).
Kabanov et al., "The Neuroleptic Activity Of Haloperidol Increases After Its Solubilization In Surfactant Micelles: Micelles As Microcontainers For Drug Targeting", FEBS Lett., 258, N 2, 343-345 (1989).
Kabanov et al., "A New Class of Drug Carriers: Micelles of Poly(oxyethylene)--Poly(oxypropylene) Block Copolymers As Microcontainers For Drug Targeting From Blood In Brain", J. Contr. Release, 22, 141-158 (1992).
Kabanov et al., "Enhancement Of Macromolecule Penetration Into Cells And Nontraditional Drug Delivery Systems", Sov. Sci. Rev. D. Physiochem. Biol. (V.P. Skulachev ed.), vol. 11, Glasgow: Harwood Academic Publishers, part 2, pp. 1-77 (1992).
Kabanov et al., "Site Specific Drug Targeting", CPhI '92 Conference Proceedings, London: Eyre & Spotiswoode Ltd., pp. 89-96 (1993).
Kabanov et al., Polymeric Surfactant Micelles As Microcontainers . . . , Journal of Neuroimmuno. (Suppl 1): 130 (1991).
Chawla et al., "Aggregation of Insulin, Containing Surfactants, in Contact with Different Materials," Diabetes. vol. 34: 420-424 (1995).
Kabanov et al., "Interpolyelectrolyte and Block Ionomer Complexes for Gene Delivery: Physicochemical Aspects," Advanced Drug Delivery Reviews, Elsevier, vol. 30: 49-60 (1998).
Batrakova, "Effects of Pluronic Block Copolymers on Drug Absorption in Caco-2 Cell Monolayers," Pharmaceutical Research, vol. 15, No. 6, (1998).
Abstract, Database WPI Week 9519, Derwent Publ. Ltd. AN 95-144714 High Water Soluble Antitumour Adriamycin Agent Comprise Micellar Complex Block Copolymer Polyethyene Glycol Poly Amino acid.
Kataoka et al., "Block Copolymer Micelles As Vehicles for Drug Delivery," Journal of Controlled Release, vol. 24: 119-132 (1993).
Alakhov Valery Yu.
Batrakova Elena V.
Chekhonin Vladimir P.
Kabanov Alexander V.
Kabanov Victor A.
Supratek Pharma Inc.
Wortman Donna C.
LandOfFree
Compositions for targeting biological agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for targeting biological agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for targeting biological agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1722130